ArticleNaunyn-Schmiedeberg's archives of pharmacology2021
Effects of repeated increasing doses of cisplatin as models of acute kidney injury and chronic kidney disease in rats.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Animal Models for Studying Protein-Bound Uremic Toxin Removal-A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Early Dose-Related Cardiorenal Effects of Cisplatin: Integrated Biochemical, Molecular and Histopathological Evaluation in an Experimental Rat Model.Biomedicines · 2026Article
- Celastrol Ameliorates Renal Injury in Spontaneously Hypertensive Rats by Activating the Nrf2/Ho-1 Signaling Pathway to Alleviate Oxidative Stress.International journal of molecular sciences · 2026Article
- Effects of high and moderate intensity exercise training on sex hormones and testicular damage induced by cisplatin in rats.BMC sports science, medicine & rehabilitation · 2025Article
- A comparative review of murine models of repeated low-dose cisplatin-induced chronic kidney disease.Lab animal · 2025Review
- Attenuation of cisplatin-induced acute kidney injury by sanguinarine: modulation of oxidative stress, inflammation, and cellular damage.Frontiers in pharmacology · 2025Article
- Insights into Repeated Renal Injury Using RNA-Seq with Two New RPTEC Cell Lines.International journal of molecular sciences · 2023Article
- Cisplatin cycles treatment sustains cardiovascular and renal damage involving TLR4 and NLRP3 pathways.Pharmacology research & perspectives · 2023Article
- Early diagnostic biomarkers for acute kidney injury using cisplatin-induced nephrotoxicity in rat model.Current research in toxicology · 2023Article
- Cisplatin-Induced Kidney Toxicity: Potential Roles of Major NADBiomolecules · 2022Review
- Exosomes Derived from BM-MSCs Mitigate the Development of Chronic Kidney Damage Post-Menopause via Interfering with Fibrosis and Apoptosis.Biomolecules · 2022Article
- Integrated analysis of comprehensive metabolomics and network pharmacology to reveal the mechanisms ofFrontiers in pharmacology · 2022Article
- The salutary action of melatonin and betaine, given singly or concomitantly, on cisplatin-induced nephrotoxicity in mice.Naunyn-Schmiedeberg's archives of pharmacology · 2021Article
- Kidney-Targeted Epoxyeicosatrienoic Acid Analog, EET-F01, Reduces Inflammation, Oxidative Stress, and Cisplatin-Induced Nephrotoxicity.International journal of molecular sciences · 2021Article
- Effect of flaxseed on systemic inflammation and oxidative stress in diabetic rats with or without chronic kidney disease.PloS one · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cisplatin (CP) is nephrotoxic, and this side effect is used as an animal model for acute kidney injury (AKI). Earlier research has been focused on CP-induced AKI, with relatively little attention being paid to its ability to progress to chronic kidney disease (CKD) on repeated administration. We aimed here to test the dose dependency of its nephrotoxic actions by comparing various physiological, biochemical, molecular, and histopathological indices using repeated increasing doses of CP in rats. Furthermore, we investigated whether these doses of CP would result in the development of CKD. Biochemical, molecular, and histopathological measurements were conducted in plasma, urine, and/or kidneys of rats treated with increasing doses of CP at 1.6, 3.2, and 4.8 mg kg
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.